| Ovarian cancer immunotherapy and personalized medicine S Morand, M Devanaboyina, H Staats, L Stanbery, J Nemunaitis International Journal of Molecular Sciences 22 (12), 6532, 2021 | 271 | 2021 |
| TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials K Choucair, S Morand, L Stanbery, G Edelman, L Dworkin, J Nemunaitis Cancer gene therapy 27 (12), 841-853, 2020 | 142 | 2020 |
| The abscopal effect of radiation therapy DJ Craig, NS Nanavaty, M Devanaboyina, L Stanbery, D Hamouda, ... Future Oncology 17 (13), 1683-1694, 2021 | 108 | 2021 |
| Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial RP Rocconi, EA Grosen, SA Ghamande, JK Chan, MA Barve, J Oh, ... The lancet oncology 21 (12), 1661-1672, 2020 | 104 | 2020 |
| Homologous recombination proficiency in ovarian and breast cancer patients JF Creeden, NS Nanavaty, KR Einloth, CE Gillman, L Stanbery, ... BMC cancer 21, 1-12, 2021 | 79 | 2021 |
| Current ovarian cancer maintenance strategies and promising new developments V Gogineni, S Morand, H Staats, R Royfman, M Devanaboyina, K Einloth, ... Journal of Cancer 12 (1), 38, 2021 | 60 | 2021 |
| Folate receptor as a biomarker and therapeutic target in solid tumors O Young, N Ngo, L Lin, L Stanbery, JF Creeden, D Hamouda, ... Current Problems in Cancer 47 (1), 100917, 2023 | 48 | 2023 |
| High SEPT9_v1 expression is associated with poor clinical outcomes in head and neck squamous cell carcinoma L Stanbery, NJ D'Silva, JS Lee, CR Bradford, TE Carey, ME Prince, ... Translational oncology 3 (4), 239-245, 2010 | 41 | 2010 |
| PIK3CA gene aberrancy and role in targeted therapy of solid malignancies O Willis, K Choucair, A Alloghbi, L Stanbery, R Mowat, ... Cancer gene therapy 27 (9), 634-644, 2020 | 38 | 2020 |
| NF-κB signaling in tumor pathways focusing on breast and ovarian cancer M Devanaboyina, J Kaur, E Whiteley, L Lin, K Einloth, S Morand, ... Oncology reviews 16, 10568, 2022 | 37 | 2022 |
| Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer RP Rocconi, BJ Monk, A Walter, TJ Herzog, E Galanis, L Manning, ... Gynecologic oncology 161 (3), 676-680, 2021 | 33 | 2021 |
| Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment S Morand, H Staats, JF Creeden, A Iqbal, B Kahaleh, L Stanbery, ... Future Oncology 16 (9), 483-495, 2020 | 32 | 2020 |
| Resident memory T cells and their effect on cancer DJ Craig, JF Creeden, KR Einloth, CE Gillman, L Stanbery, D Hamouda, ... Vaccines 8 (4), 562, 2020 | 30 | 2020 |
| Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance J Oh, M Barve, N Senzer, P Aaron, L Manning, G Wallraven, E Bognar, ... Gynecologic Oncology Reports 34, 100648, 2020 | 26 | 2020 |
| Adenomatous polyposis coli in cancer and therapeutic implications O Noe, L Filipiak, R Royfman, A Campbell, L Lin, D Hamouda, L Stanbery, ... Oncology Reviews 15 (1), 534, 2021 | 25 | 2021 |
| Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer RP Rocconi, EE Stevens, JN Bottsford-Miller, SA Ghamande, J Elder, ... Cancer gene therapy 29 (3), 369-382, 2022 | 23 | 2022 |
| Bifidobacterium SPP: The Promising Trojan Horse in the Era of Precision Oncology N Ngo, K Choucair, JF Creeden, H Qaqish, K Bhavsar, C Murphy, K Lian, ... Future Oncology 15 (33), 3861-3876, 2019 | 23 | 2019 |
| SEPT9_i1 and genomic instability: mechanistic insights and relevance to tumorigenesis EA Peterson, L Stanbery, C Li, H Kocak, O Makarova, EM Petty Genes, Chromosomes and Cancer 50 (11), 940-949, 2011 | 22 | 2011 |
| FDA efficiency for approval process of COVID-19 therapeutics C Cassidy, D Dever, L Stanbery, G Edelman, L Dworkin, J Nemunaitis Infectious Agents and Cancer 15, 1-13, 2020 | 21 | 2020 |
| BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target S Morand, L Stanbery, A Walter, RP Rocconi, J Nemunaitis JNCI Cancer Spectrum 4 (6), pkaa077, 2020 | 19 | 2020 |
